TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial
Treatment with adjuvant TAGRISSO reduced the risk of death by more than half ... | June 4, 2023